Search

Displaying results 6821 - 6830 of 8696 in total
  1. Drug

    Pegdinetanib

    go.drugbank.com/drugs/DB05931
    Investigational

    As a result, CT-322 blocks all known ligands for VEGFR-2. … CT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis

    Categories: Vascular Endothelial Growth Factor Receptor-2, antagonists & inhibitors
  2. Drug

    Trepibutone

    go.drugbank.com/drugs/DB13311
    Experimental

    Categories: Drugs for Functional Gastrointestinal Disorders
  3. Drug

    Pyrrolnitrin

    go.drugbank.com/drugs/DB13603
    Experimental

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  4. Drug

    Livmoniplimab

    go.drugbank.com/drugs/DB18939
    Investigational

    With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)). … Livmoniplimab is under investigation in clinical trial NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination

  5. Drug

    Jaktinib

    go.drugbank.com/drugs/DB17545
    Investigational

    Jaktinib is under investigation in clinical trial NCT04866056 (Jaktinib and Azacitidine in Treating Patients With MDS With MF or MDS/MPN With MF.).

  6. Drug

    Cyanamide

    go.drugbank.com/drugs/DB02679
    Experimental

    A cyanide compound which has been used as a fertilizer, defoliant and in many manufacturing processes. It often occurs as the calcium salt, sometimes also referred to as cyanamide.

  7. Drug

    MLN8054

    go.drugbank.com/drugs/DB13061
    Investigational

    MLN8054 has been used in trials studying the treatment of Colon Neoplasm, Breast Neoplasm, Bladder Neoplasm, Pancreatic Neoplasm, and Advanced Malignancies.

  8. Drug

    Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB21765
    Approved

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  9. Drug

    Influenza A virus A/West Virginia/30/2022 (H1N1) Recombinant Hemagglutinin Antigen

    go.drugbank.com/drugs/DB17995
    ApprovedWithdrawn

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  10. Drug

    Influenza A virus A/Georgia/12/2022 CVR-167 (H1N1) Antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB17996
    Approved

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen